Journal: Biochemistry

Article Title: Design of Mimetic Antibodies Targeting the SARS-CoV-2 Spike Glycoprotein Based on the GB1 Domain: A Molecular Simulation and Experimental Study

doi: 10.1021/acs.biochem.4c00671

Figure Lengend Snippet: Chart showing the percentage of inhibition of purified extracts containing GB1-REF and SGB1–121. Inhibition values above 30% are considered positive. All samples are normalized using the cPass negative control.

Article Snippet: To experimentally confirm the ability of MA to neutralize RBD, we performed the commercially available cPass ELISA kit, purchased from GenScript, the protocol of which is shown in the SI .

Techniques: Inhibition, Purification, Negative Control

Journal: Kidney360

Article Title: Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis

doi: 10.34067/KID.0004372021

Figure Lengend Snippet: Longitudinal results from end-stage renal disease (ESRD) participants on maintenance dialysis. (A) Longitudinal results including RT-PCR, viral culture, symptom onset, SARS-CoV-2–specific antibodies, and positive neutralizing antibodies from participants with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15). (B) Longitudinal results including RT-PCR, viral cultures, symptom onset, and positive and negative symptoms from participants with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15). Thirteen participants completed the assessment. Participants D and K withdrew before the end of the assessment. Day of diagnosis is displayed as day 0 on the x axis and represents the day of diagnosis recorded in the facility’s medical record (either RT-PCR or antigen test). For each visit, a composite RT-PCR result was determined on the basis of available RT-PCR results from all specimens collected at each visit (oropharyngeal, anterior nasal, and saliva). We defined RT-PCR positivity as having any of the three specimens RT-PCR positive, inconclusive if there was no positive RT-PCR but at least one inconclusive test, and negative if all specimens were negative by RT-PCR. Antibody to the SARS-CoV-2 spike protein was positive if ≥100. Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit. Group 1: diagnosis of SARS-CoV-2 infection was ≤5 days before enrollment. Group 2: diagnosis of SARS-CoV-2 infection was 6–15 days before enrollment. Group 3: diagnosis of SARS-CoV-2 infection was >15 days before enrollment and evidence of recent RT-PCR positivity (i.e., positive RT-PCR ≤5 days of enrollment). Symptomatic was defined as reporting any symptoms from the coronavirus disease 2019 symptoms list (included in Table 1) during a particular visit. Participant A had rheumatoid arthritis and was taking 5 mg/d prednisone. Participants D and H had a history of kidney allograft failure and were taking immunosuppressive medications. Participant L received convalescent plasma and Ig in the first 2 days after diagnosis. The remaining patients had no immunosuppressive conditions. ID, identifier; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit.

Techniques: Reverse Transcription Polymerase Chain Reaction, Infection, Biomarker Discovery, Neutralization, Inhibition, Medications, Clinical Proteomics

Journal: Kidney360

Article Title: Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis

doi: 10.34067/KID.0004372021

Figure Lengend Snippet: Detection of SARS-CoV-2 neutralizing antibodies among patients with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15) since diagnosis. Surrogate neutralization antibodies were measured using the Genscript cPass Surrogate Neutralization Kit. The results are presented as percentages and represent the percent that particular serum specimen blocked the interaction between the SARs-CoV-2 receptor binding domain and the angiotensin-converting enzyme 2 cellular receptor. The higher the number, the more surrogate neutralization activity; ≥70% (dashed line) was considered positive. Participant A had rheumatoid arthritis and was taking 5 mg/d prednisone. Participants D and H had a history of kidney allograft failure and were taking immunosuppressive medications. Participant L received convalescent plasma and Ig in the first 2 days after diagnosis. Participants D and K withdrew before the end of the assessment. Participants D and E did not have documented seroconversion. ID, identifier.

Article Snippet: Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit.

Techniques: Infection, Biomarker Discovery, Neutralization, Binding Assay, Activity Assay, Medications, Clinical Proteomics